Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
CBT 200 Falls 67 Points. More details...
A List Of Players To Watch. More details...
CBT 200 Rises 39 Points. More details...
Tarceva Gets Another FDA Approval. More details...
CBT 200 Gains 62 Points. More details...
Positive Results From Initial Tests. More details...
CBT 200 Threatens To Top Recent Highs. More details...
Poor Growth Predicted. More details...
CBT 200 Down A Fraction. More details...
Is The Stock Undervalued?. More details...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
